References
- Norman JE, Beebe GW, Hoofnagle JH, et al. Mortality follow-up of the 1942 epidemic of hepatitis B in the U.S. Army. Hepatology 1993; 18(4):790–7
- Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic Factors for chronic hepatitis type B. Gut 1991; 32(3):294–8
- McMahon BJ, Alberts SR, Wainwright RB, et al. Hepatitis B-related sequelae: prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150(5):1051–4
- Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion- associated non-A, non-B hepatitis. N Engl J Med 1992; 327(27): 1906–11
- Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12(4 Pt 1):671–5
- Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327(27): 1899–905
- Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995: 346(8982): 1051–5
- Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24:141–7
- Guido M, Rugge M, Chemello L, et al. Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. J Hepatol 1996;24:301–7
- Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995; 22(6): 1863–73
- Wong JB, Koff RS, Tine F, et al. Cost- effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122(9):664–75
- Dusheiko GM, Khakoo S, Soni P, et al. A rational approach to the management of hepatitis C infection. BMJ 1996;312(7027):357–64
- Booth JC, Brown JL, Thomas HC. The management of chronic hepatitis C virus infection. Gut 1995;37(4):449–54
References
- Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346(8982): 1051–5
- Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24:141–7
- Kuroki T, Nishiguchi S, Nakatani S. Interferon and hepatocellular carcinoma. (Letter response) Lancet 1996; 347(8995):194–5
- Wong JB, Koff RS, Tine F, et al. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122(9):664–75